Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 74.02

-0.6%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2033)	6/11/1998 2:30:00 AM
From: marc ultra	Read Replies (1) of 4676

I think deal with Merck is important since we don't really know where 2302 is going, hopefully pivotal trial for Chrohn's will do OK but don't know and other indications less clear. RA would be a big one but as far as I know no news on this. AIDS drug apparently a flop, not worth further development and cancer drugs unclear how useful. So the one apparent clear winner to date is Fomvirisen which while not a big money maker if approved it does establish antisense for infectious disease and this direction specifically antiviral may be a good place to establish itself now. One interesting thing I saw was that CMV was able to develop resistance to Fomvirissen in some in vitro assay and I wonder how much of a problem this may be and if such problems can be easily solved by tinkering with the length or site of action of the oligonucleotide. Anyway another four or five good news items and we'll probably have the stock down to 10

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next